CL2020000856A1 - Isoquinolinas como inhibidores de hpk1. (divisional solicitud 201902734) - Google Patents
Isoquinolinas como inhibidores de hpk1. (divisional solicitud 201902734)Info
- Publication number
- CL2020000856A1 CL2020000856A1 CL2020000856A CL2020000856A CL2020000856A1 CL 2020000856 A1 CL2020000856 A1 CL 2020000856A1 CL 2020000856 A CL2020000856 A CL 2020000856A CL 2020000856 A CL2020000856 A CL 2020000856A CL 2020000856 A1 CL2020000856 A1 CL 2020000856A1
- Authority
- CL
- Chile
- Prior art keywords
- hpk1
- inhibitors
- isoquinolines
- methods
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101100177670 Caenorhabditis elegans hpk-1 gene Proteins 0.000 title 1
- 150000002537 isoquinolines Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical class C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000003394 haemopoietic effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE DESCRIBEN COMPUESTOS DE ISOQUINOLINA Y SU USO COMO INHIBIDORES DE HPK1 (QUINASA HEMATOPOYÉTICA 1). LOS COMPUESTOS SON DE UTILIDAD PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE HPK1 Y MEJORA DE UNA RESPUESTA INMUNE. TAMBIÉN SE DESCRIBEN MÉTODOS DE INHIBICIÓN DE HPK1, MÉTODOS DE TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE LA HPK1, MÉTODOS PARA MEJORAR UNA RESPUESTA INMUNE Y MÉTODOS PARA PREPARAR LOS COMPUESTOS DE ISOQUINOLINA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017078790 | 2017-03-30 | ||
CN2018076908 | 2018-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020000856A1 true CL2020000856A1 (es) | 2020-08-21 |
Family
ID=62002510
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019002734A CL2019002734A1 (es) | 2017-03-30 | 2019-09-25 | Isoquinolinas como inhibidores de hpk1. |
CL2020000856A CL2020000856A1 (es) | 2017-03-30 | 2020-03-31 | Isoquinolinas como inhibidores de hpk1. (divisional solicitud 201902734) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019002734A CL2019002734A1 (es) | 2017-03-30 | 2019-09-25 | Isoquinolinas como inhibidores de hpk1. |
Country Status (20)
Country | Link |
---|---|
US (2) | US20180282282A1 (es) |
EP (1) | EP3601259B1 (es) |
JP (1) | JP7129420B6 (es) |
KR (1) | KR20190135029A (es) |
CN (2) | CN117024411A (es) |
AU (1) | AU2018243770A1 (es) |
BR (1) | BR112019019555A2 (es) |
CA (1) | CA3054161A1 (es) |
CL (2) | CL2019002734A1 (es) |
CO (1) | CO2019009927A2 (es) |
CR (1) | CR20190424A (es) |
IL (1) | IL268994A (es) |
MA (1) | MA48994A (es) |
MX (1) | MX2019010302A (es) |
PE (1) | PE20200008A1 (es) |
PH (1) | PH12019502258A1 (es) |
RU (1) | RU2019133646A (es) |
SG (2) | SG11201908940UA (es) |
TW (1) | TW201843139A (es) |
WO (1) | WO2018183964A1 (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11866450B2 (en) | 2018-02-15 | 2024-01-09 | Vertex Pharmaceuticals Incorporated | Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3570844T3 (pl) | 2017-01-20 | 2024-02-26 | Arcus Biosciences, Inc. | Azolopirymidyna do leczenia zaburzeń związanych z nowotworami |
JOP20180029A1 (ar) | 2017-03-30 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب حلقي غير متجانس |
AU2018243770A1 (en) | 2017-03-30 | 2019-09-19 | F. Hoffmann-La Roche Ag | Isoquinolines as inhibitors of HPK1 |
CN109111464B (zh) * | 2017-06-23 | 2021-02-26 | 爱科诺生物医药股份有限公司 | 一种具有细胞坏死抑制活性的杂环化合物 |
US10604514B2 (en) | 2017-10-19 | 2020-03-31 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
US10413537B2 (en) | 2017-10-27 | 2019-09-17 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof |
WO2019084497A1 (en) | 2017-10-27 | 2019-05-02 | Samumed, Llc | 6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE |
US10703748B2 (en) | 2017-10-31 | 2020-07-07 | Samumed, Llc | Diazanaphthalen-3-yl carboxamides and preparation and use thereof |
US11166959B2 (en) | 2017-11-06 | 2021-11-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as HPK1 inhibitors |
MX2020008404A (es) | 2018-02-13 | 2020-09-25 | Gilead Sciences Inc | Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1). |
CA3090922A1 (en) | 2018-02-16 | 2019-08-22 | Arcus Biosciences, Inc. | Dosing with an azolopyrimidine compound |
CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
AU2019301811B2 (en) | 2018-07-13 | 2022-05-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP7386841B2 (ja) * | 2018-07-24 | 2023-11-27 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | イソキノリン化合物及びその使用 |
CN113454070A (zh) * | 2018-09-30 | 2021-09-28 | 豪夫迈·罗氏有限公司 | 噌啉化合物及用于hpk1依赖性疾患诸如癌症的治疗 |
TW202024053A (zh) * | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
JP2022504080A (ja) * | 2018-10-03 | 2022-01-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 8-アミノイソキノリン化合物およびその使用 |
CN117105933A (zh) * | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
KR102650496B1 (ko) | 2018-10-31 | 2024-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제제로서의 치환된 6-아자벤즈이미다졸 화합물 |
EP3894406A1 (en) | 2018-12-11 | 2021-10-20 | Bayer Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
MX2021007426A (es) | 2018-12-20 | 2021-09-08 | Incyte Corp | Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina. |
AU2020249409A1 (en) | 2019-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | HPK1 inhibitors |
CA3129772A1 (en) | 2019-03-26 | 2020-10-01 | Janssen Pharmaceutica Nv | Bicyclic hpk1 inhibitors |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
WO2021004547A1 (en) * | 2019-07-11 | 2021-01-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of hpk1 |
PL4045083T3 (pl) | 2019-10-18 | 2024-05-13 | Forty Seven, Inc. | Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej |
MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
AU2020412875A1 (en) | 2019-12-24 | 2022-06-23 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
AU2021219668A1 (en) | 2020-02-14 | 2022-08-25 | Gilead Sciences, Inc. | Antibodies and fusion proteins that bind to CCR8 and uses thereof |
CN113336747A (zh) * | 2020-03-03 | 2021-09-03 | 轶诺(浙江)药业有限公司 | 新型hpk1抑制剂及其制备方法和应用 |
MX2022013619A (es) | 2020-05-01 | 2022-11-16 | Gilead Sciences Inc | Compuestos de 2,4-dioxopirimidina que inhiben cd73. |
WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
JP2023549682A (ja) * | 2020-10-29 | 2023-11-29 | メルク・シャープ・アンド・ドーム・エルエルシー | Lrrk2阻害薬としてのn-結合イソキノリンアミド、医薬組成物及びその使用 |
CN114437074A (zh) | 2020-11-03 | 2022-05-06 | 北京伯汇生物技术有限公司 | 一种化合物、含该化合物的药物组合物及其用途 |
US20230399341A1 (en) * | 2020-11-09 | 2023-12-14 | Merck Sharp & Dohme Llc | 7-phenyl substituted 2-aminoquinazoline inhibitors of hpk1 |
CN114516857A (zh) * | 2020-11-20 | 2022-05-20 | 深圳智药信息科技有限公司 | Hpk1抑制剂及其用途 |
CN112625030A (zh) * | 2020-12-25 | 2021-04-09 | 杭州澳赛诺生物科技有限公司 | 一种一锅法合成n-保护3-溴代吡唑的合成方法 |
EP4288437A1 (en) | 2021-02-05 | 2023-12-13 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
WO2022222951A1 (zh) * | 2021-04-22 | 2022-10-27 | 浙江海正药业股份有限公司 | 芳香稠合环类衍生物及其制备方法和用途 |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117693503A (zh) | 2021-07-20 | 2024-03-12 | 阿斯利康(瑞典)有限公司 | 作为hpk1抑制剂用于治疗癌症的经取代的吡嗪-2-甲酰胺 |
CN115838373A (zh) | 2021-09-18 | 2023-03-24 | 北京伯汇生物技术有限公司 | 氮杂吲唑大环化合物及其用途 |
WO2023055679A1 (en) * | 2021-10-01 | 2023-04-06 | Merck Sharp & Dohme Llc | C-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
TW202330504A (zh) | 2021-10-28 | 2023-08-01 | 美商基利科學股份有限公司 | 嗒𠯤—3(2h)—酮衍生物 |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
CN116672450A (zh) * | 2022-02-23 | 2023-09-01 | 智宠制药(北京)有限公司 | Hpk1抑制剂在治疗干扰素相关疾病中的应用 |
US20230373950A1 (en) | 2022-03-17 | 2023-11-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
TW202400612A (zh) * | 2022-05-10 | 2024-01-01 | 德商馬克專利公司 | 作為HPK1抑制劑之四氫吡啶并[3,4-d]嘧啶化物 |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
DE3034001A1 (de) | 1980-09-10 | 1982-04-22 | Hoechst Ag, 6000 Frankfurt | Isochinolinderivate, verfahren zu ihrer hersellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung |
PL176081B1 (pl) | 1995-06-06 | 1999-04-30 | Politechnika Warszawska | Sposób wytwarzania 3-aminoizochinoliny i jej N-mono oraz N,N-dipodstawionych pochodnych |
JP2003500383A (ja) | 1999-05-24 | 2003-01-07 | コア・セラピューティクス,インコーポレイテッド | 第Xa因子阻害剤 |
US7199149B2 (en) | 2003-10-01 | 2007-04-03 | Bristol Myers Squibb Company | Monocyclic and bicyclic lactams as factor Xa inhibitors |
US20090143399A1 (en) | 2003-10-14 | 2009-06-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
US20090099165A1 (en) | 2003-10-14 | 2009-04-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
JP2007008816A (ja) | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
US20060156485A1 (en) | 2005-01-14 | 2006-07-20 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
PT1899322E (pt) | 2005-06-28 | 2009-11-09 | Sanofi Aventis | Derivados de isoquinolina como inibidores de rho-cinase |
CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
WO2007041511A2 (en) | 2005-09-30 | 2007-04-12 | New York University | Hematopoietic progenitor kinase 1 for modulation of an immune response |
DOP2006000233A (es) | 2005-10-28 | 2007-06-15 | Lilly Co Eli | Inhibidores de cinasa |
US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
US7514566B2 (en) | 2006-01-18 | 2009-04-07 | Amgen, Inc. | Thiazole compounds and methods of use |
JP2009535393A (ja) | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換2−アミノ縮合複素環式化合物 |
CA2673920C (en) | 2006-12-27 | 2015-03-24 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline derivatives |
EP1975166A1 (en) | 2007-03-30 | 2008-10-01 | Bayer Schering Pharma AG | Synthesis of anthranilamides |
JP2010524885A (ja) | 2007-04-17 | 2010-07-22 | ノバルティス アーゲー | がん治療剤としてのナフタレンカルボン酸アミドのエーテル |
EP2008658A1 (en) | 2007-06-28 | 2008-12-31 | Bayer Schering Pharma Aktiengesellschaft | Synergistic combination of anthranilamide pyridinureas and benzamide derivatives |
EP2195328A4 (en) | 2007-08-15 | 2011-06-15 | Cytokinetics Inc | PARTICULAR CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS |
GB0803018D0 (en) * | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
US8309577B2 (en) | 2008-04-23 | 2012-11-13 | Bristol-Myers Squibb Company | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands |
GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
JP2012510429A (ja) | 2008-08-25 | 2012-05-10 | アンプリミューン、インコーポレーテッド | Pd−1アンタゴニストおよびその使用方法 |
TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
CA2899583A1 (en) | 2009-12-16 | 2011-06-23 | Pfizer Inc. | N-linked hydroxamic acid derivatives useful as antibacterial agents |
CN104530079B (zh) | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
CA2793975A1 (en) * | 2010-03-31 | 2011-10-10 | Actelion Pharmaceuticals Ltd | Antibacterial isoquinolin-3-ylurea derivatives |
ES2546465T3 (es) | 2010-10-29 | 2015-09-23 | Pfizer Inc | Inhibidores de N1/N2-lactama acetil-CoA carboxilasa |
US8623889B2 (en) | 2010-12-17 | 2014-01-07 | Genentech, Inc. | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
SG193458A1 (en) | 2011-04-08 | 2013-10-30 | Pfizer | Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
CN103857675A (zh) | 2011-06-23 | 2014-06-11 | 威尔金制药有限公司 | 金属酶抑制剂化合物 |
WO2013003315A2 (en) | 2011-06-26 | 2013-01-03 | President And Fellows Of Harvard College | Methods for preparing isoquinolines |
WO2013169793A2 (en) | 2012-05-09 | 2013-11-14 | Ipierian, Inc. | Methods and compositions for tdp-43 proteinopathies |
KR20150047597A (ko) | 2012-08-27 | 2015-05-04 | 어레이 바이오파마 인크. | 과증식성 질환의 치료를 위한 세린/트레오닌 키나아제 억제제 |
GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
AU2013315528A1 (en) | 2012-09-14 | 2015-03-12 | Eternity Bioscience Inc. | Aminoisoquinoline derivatives as protein kinase inhibitors |
WO2014123900A1 (en) | 2013-02-05 | 2014-08-14 | Sirenas Marine Discovery | Anti-cancer and anti-hiv compounds |
EP3016946B1 (en) | 2013-07-03 | 2022-10-12 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and pharmaceutical uses thereof |
WO2016014674A1 (en) | 2014-07-22 | 2016-01-28 | University Of Maryland, College Park | Linked diaryl compounds with anticancer properties and methods of using the same |
US20160158360A1 (en) | 2014-12-05 | 2016-06-09 | Genentech, Inc. | Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists |
SG10202105964RA (en) * | 2015-06-25 | 2021-07-29 | Univ Health Network | Hpk1 inhibitors and methods of using same |
WO2017069980A1 (en) | 2015-10-20 | 2017-04-27 | Forum Pharmaceuticals, Inc. | Aminoisoxazoline compounds as agonists of alpha7-nicotinic acetylcholine receptors |
CN108430993A (zh) | 2015-12-17 | 2018-08-21 | 吉利德科学公司 | Tank-结合激酶抑制剂化合物 |
MA43811A (fr) | 2016-03-07 | 2018-11-28 | Merck Sharp & Dohme | Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes |
CN107163022B (zh) | 2016-03-07 | 2021-07-16 | 上海如絮生物科技有限公司 | 一种异喹啉类化合物、其中间体、制备方法和应用 |
GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
CN107266421B (zh) | 2016-04-08 | 2020-12-04 | 正大天晴药业集团股份有限公司 | 取代的苯并咪唑类衍生物 |
AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
WO2018049191A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
US11180482B2 (en) | 2016-11-30 | 2021-11-23 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors |
US20180177784A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
PL3570844T3 (pl) | 2017-01-20 | 2024-02-26 | Arcus Biosciences, Inc. | Azolopirymidyna do leczenia zaburzeń związanych z nowotworami |
JOP20180029A1 (ar) | 2017-03-30 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب حلقي غير متجانس |
AU2018243770A1 (en) | 2017-03-30 | 2019-09-19 | F. Hoffmann-La Roche Ag | Isoquinolines as inhibitors of HPK1 |
JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Mcl−1タンパク質を阻害する化合物 |
BR112019026478A2 (pt) | 2017-06-14 | 2020-07-14 | Trevena, Inc. | compostos para modulação da atividade de s1p1 e métodos de uso dos mesmos |
US10604514B2 (en) | 2017-10-19 | 2020-03-31 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
WO2019084497A1 (en) | 2017-10-27 | 2019-05-02 | Samumed, Llc | 6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE |
EP3752492B1 (en) | 2018-02-12 | 2022-12-21 | Bayer Aktiengesellschaft | Fungicidal oxadiazoles |
JP7386841B2 (ja) | 2018-07-24 | 2023-11-27 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | イソキノリン化合物及びその使用 |
TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
JP2022504080A (ja) | 2018-10-03 | 2022-01-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 8-アミノイソキノリン化合物およびその使用 |
-
2018
- 2018-03-30 AU AU2018243770A patent/AU2018243770A1/en not_active Abandoned
- 2018-03-30 CN CN202310812033.5A patent/CN117024411A/zh active Pending
- 2018-03-30 EP EP18718381.9A patent/EP3601259B1/en active Active
- 2018-03-30 RU RU2019133646A patent/RU2019133646A/ru not_active Application Discontinuation
- 2018-03-30 CN CN201880033672.9A patent/CN110709392B/zh active Active
- 2018-03-30 TW TW107111420A patent/TW201843139A/zh unknown
- 2018-03-30 US US15/942,333 patent/US20180282282A1/en not_active Abandoned
- 2018-03-30 JP JP2019553484A patent/JP7129420B6/ja active Active
- 2018-03-30 MX MX2019010302A patent/MX2019010302A/es unknown
- 2018-03-30 CR CR20190424A patent/CR20190424A/es unknown
- 2018-03-30 CA CA3054161A patent/CA3054161A1/en active Pending
- 2018-03-30 BR BR112019019555A patent/BR112019019555A2/pt not_active Application Discontinuation
- 2018-03-30 KR KR1020197031954A patent/KR20190135029A/ko not_active Application Discontinuation
- 2018-03-30 WO PCT/US2018/025573 patent/WO2018183964A1/en unknown
- 2018-03-30 MA MA048994A patent/MA48994A/fr unknown
- 2018-03-30 SG SG11201908940U patent/SG11201908940UA/en unknown
- 2018-03-30 PE PE2019001747A patent/PE20200008A1/es unknown
- 2018-03-31 SG SG10201914112VA patent/SG10201914112VA/en unknown
-
2019
- 2019-08-29 IL IL26899419A patent/IL268994A/en unknown
- 2019-09-12 CO CONC2019/0009927A patent/CO2019009927A2/es unknown
- 2019-09-25 CL CL2019002734A patent/CL2019002734A1/es unknown
- 2019-09-30 PH PH12019502258A patent/PH12019502258A1/en unknown
-
2020
- 2020-03-31 CL CL2020000856A patent/CL2020000856A1/es unknown
- 2020-07-06 US US16/921,297 patent/US11566003B2/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11866450B2 (en) | 2018-02-15 | 2024-01-09 | Vertex Pharmaceuticals Incorporated | Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
Also Published As
Publication number | Publication date |
---|---|
CN110709392B (zh) | 2023-09-29 |
CN117024411A (zh) | 2023-11-10 |
CL2019002734A1 (es) | 2020-01-17 |
WO2018183964A1 (en) | 2018-10-04 |
PE20200008A1 (es) | 2020-01-06 |
IL268994A (en) | 2019-10-31 |
SG11201908940UA (en) | 2019-10-30 |
BR112019019555A2 (pt) | 2020-04-22 |
MX2019010302A (es) | 2019-11-21 |
JP2020515603A (ja) | 2020-05-28 |
CA3054161A1 (en) | 2018-10-04 |
CR20190424A (es) | 2019-11-04 |
RU2019133646A (ru) | 2021-04-30 |
RU2019133646A3 (es) | 2021-07-30 |
MA48994A (fr) | 2020-02-05 |
JP7129420B2 (ja) | 2022-09-01 |
EP3601259A1 (en) | 2020-02-05 |
KR20190135029A (ko) | 2019-12-05 |
PH12019502258A1 (en) | 2020-07-06 |
AU2018243770A1 (en) | 2019-09-19 |
TW201843139A (zh) | 2018-12-16 |
JP7129420B6 (ja) | 2024-02-02 |
CO2019009927A2 (es) | 2019-09-30 |
US20210163417A1 (en) | 2021-06-03 |
US20180282282A1 (en) | 2018-10-04 |
SG10201914112VA (en) | 2020-03-30 |
US11566003B2 (en) | 2023-01-31 |
EP3601259B1 (en) | 2022-02-23 |
CN110709392A (zh) | 2020-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020000856A1 (es) | Isoquinolinas como inhibidores de hpk1. (divisional solicitud 201902734) | |
ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
UY37381A (es) | Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos | |
CL2017001050A1 (es) | Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
CR20150524A (es) | Compuestos de heteroarilo y sus usos | |
CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
ECSP15043696A (es) | Compuestos de heteroarilo y sus usos | |
CL2016001895A1 (es) | Compuestos | |
CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
EA202090291A3 (ru) | Производные бипиразола в качестве ингибиторов jak | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
BR112018011319A2 (pt) | novos anticorpos anti-claudina e métodos de uso | |
CL2016001973A1 (es) | Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
CL2017003107A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
CL2019001330A1 (es) | Inhibidores de la tirosina quinasa de bruton. | |
JO3794B1 (ar) | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون | |
SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
MX2018007219A (es) | Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
CO2020007895A2 (es) | Inhibidores de histona acetiltransferasa de la familia myst |